RA Capital Management L.P. Has $25.42 Million Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

RA Capital Management L.P. lessened its holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) by 10.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,563,211 shares of the company's stock after selling 535,000 shares during the quarter. RA Capital Management L.P. owned about 9.87% of 4D Molecular Therapeutics worth $25,417,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. KLP Kapitalforvaltning AS purchased a new stake in shares of 4D Molecular Therapeutics during the fourth quarter worth about $48,000. PNC Financial Services Group Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 66.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company's stock worth $51,000 after acquiring an additional 3,630 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in shares of 4D Molecular Therapeutics by 5,291.8% in the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company's stock valued at $55,000 after buying an additional 9,737 shares during the period. Virtus ETF Advisers LLC lifted its position in shares of 4D Molecular Therapeutics by 173.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,333 shares of the company's stock worth $58,000 after purchasing an additional 6,560 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in shares of 4D Molecular Therapeutics during the fourth quarter worth $69,000. Hedge funds and other institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Stock Down 13.3 %

Shares of FDMT stock traded down $0.47 during trading hours on Tuesday, reaching $3.10. 185,664 shares of the stock traded hands, compared to its average volume of 829,091. 4D Molecular Therapeutics, Inc. has a 1-year low of $2.24 and a 1-year high of $28.93. The firm has a market capitalization of $143.42 million, a PE ratio of -1.09 and a beta of 2.87. The business has a fifty day moving average price of $3.47 and a 200 day moving average price of $5.40.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.10). Research analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Royal Bank of Canada lowered their target price on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating for the company in a report on Monday, March 3rd. Morgan Stanley dropped their price objective on 4D Molecular Therapeutics from $8.00 to $6.00 and set an "underweight" rating on the stock in a report on Monday, January 13th. HC Wainwright restated a "buy" rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. Bank of America lowered their price target on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. Finally, Chardan Capital reduced their price objective on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $26.71.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.